The trial was designed as a prospective, open-label, multicenter, active-controlled study conducted across 31 clinical sites in India, enrolling healthy infants who had never received a pneumococcal conjugate vaccine. Participants aged 6 to 8 weeks at enrollment received three primary doses of either BE-PCV14 or Prevenar 13, followed by a booster dose administered at 12 to 15 months of age, a regimen commonly described as a 3p plus 1 schedule. The investigators, led by Subhash Thuluva of Biological E Limited in Hyderabad, measured serotype-specific immunoglobulin G antibodies against all 14 vaccine serotypes as well as the cross-protective serotype 6A, assessed 28 days after the booster dose. The primary immunological benchmarks were seroresponse rates, defined as the proportion of children achieving serotype-specific IgG concentrations of at least 0.35 micrograms per milliliter, a threshold long used as a correlate of protection against invasive pneumococcal disease, along with geometric mean concentrations of antibody.

The immunogenicity analysis included 559 children who received BE-PCV14 and 147 who received PCV13, providing a substantial evidence base for the comparison. The results were striking in their consistency: after the booster dose, seroresponse rates with BE-PCV14 reached at least 92.8 percent for every one of the 14 vaccine serotypes, and climbed to 96.2 percent for serotype 6A, which is not itself in the vaccine but is known to elicit cross-protection through immunological relatedness to vaccine serotype 6B. For the serotypes shared between the two vaccines, the immune responses elicited by BE-PCV14 were comparable to those generated by Prevenar 13, and post hoc statistical analyses formally demonstrated non-inferiority for all 14 serotypes by both seroresponse and antibody concentration criteria.

The non-inferiority assessment deserves particular attention because of its methodological rigor. The investigators pre-specified that BE-PCV14 would be considered non-inferior to PCV13 for a given serotype if the lower bound of the 95 percent confidence interval for the difference in seroresponse rates exceeded minus 10 percent, and if the lower bound of the confidence interval for the ratio of geometric mean concentrations exceeded 0.5. These are the kinds of thresholds that regulators and vaccine advisory bodies use to judge whether a new product can reasonably substitute for an established one. BE-PCV14 cleared both hurdles for all 14 serotypes, a result that, in the words of the trial team, establishes the vaccine as a credible alternative within existing infant immunization schedules rather than an entirely new paradigm requiring altered dosing strategies.

Perhaps the most consequential finding involves serotypes 22F and 33F, the two additional strains incorporated into BE-PCV14 that are absent from PCV13. The vaccine induced strong antibody responses to both, with booster-induced increases in antibody concentration ranging from 2.4-fold to 5.3-fold across serotypes when compared with pre-booster levels. This matters because pneumococcal serotype replacement is a well-documented phenomenon: when a vaccine eliminates the strains it targets, other strains that were previously less common can expand to fill the ecological vacuum. Serotypes 22F and 33F have been increasingly recognized as causes of invasive pneumococcal disease in countries that have deployed PCV13 at scale, and their inclusion in a new vaccine represents a forward-looking strategy intended to stay ahead of shifting disease epidemiology rather than merely replicate existing coverage.

Safety data from the trial were equally reassuring. Adverse events occurred at similarly low frequencies in both vaccine groups and were predominantly mild local reactions, such as injection-site tenderness or redness, or transient fever. Only two serious adverse events were recorded among BE-PCV14 recipients, and the investigators judged neither to be related to vaccination. The safety profile through 28 days after the booster dose, therefore, mirrors the well-characterized tolerability of licensed pneumococcal conjugate vaccines, an essential consideration for a product intended for universal infant immunization in resource-constrained settings where health systems may have limited capacity to manage vaccine-associated complications.

The trial, registered prospectively with the Clinical Trials Registry of India under identifier CTRI/2023/09/057894 and approved by India’s Central Drugs Standard Control Organisation, was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines, with written informed consent obtained from the parents or legally authorized representatives of all participants. Ethics committees overseeing each of the 31 participating sites granted approval, including the Institutional Ethics Committee of the All India Institute of Medical Sciences. The study, funded entirely by Biological E Limited, carries the inherent limitation that many of the authors are or were employees of the sponsoring company, though the trial’s active-controlled design against a licensed comparator and its prespecified statistical criteria provide meaningful safeguards against bias in the immunogenicity conclusions.

The public health significance of this work extends well beyond India’s borders. Streptococcus pneumoniae is responsible for hundreds of thousands of deaths among children under five each year, with the overwhelming majority occurring in low- and middle-income countries where access to effective vaccines has historically lagged behind wealthy nations. Pneumococcal conjugate vaccines have traditionally been among the most expensive components of childhood immunization schedules, and the introduction of a WHO-prequalified vaccine manufactured in a middle-income country carries the potential to lower prices, expand supply, and reduce dependence on a small number of multinational manufacturers. For India, which runs one of the largest immunization programs in the world through its Universal Immunization Programme, a domestically produced 14-valent vaccine that slots into the standard 3-plus-1 schedule offers both strategic and epidemiological advantages.

The trial’s findings also speak to a broader evolution in pneumococcal vaccine science. The 0.35 micrograms per milliliter IgG threshold used in this study is a population-level benchmark derived from efficacy trials of earlier conjugate vaccines, and while it does not guarantee individual protection, it remains the standard immunological bridge for licensure and comparison of new formulations. The demonstrated booster response, with antibody concentrations rising severalfold after the toddler dose, indicates that BE-PCV14 successfully exploits the immunological memory established during the primary series, an attribute that underpins the durability of protection in the second year of life, when the burden of invasive pneumococcal disease and pneumonia peaks in unvaccinated populations.

As pneumococcal disease patterns continue to shift under the selective pressure of global vaccination, the arrival of a well-tolerated, immunogenic 14-valent conjugate vaccine that extends coverage to emerging serotypes while matching the performance of the established 13-valent standard represents a meaningful advance. The authors conclude that PNEUBEVAX 14, when used as a booster in a 3-plus-1 schedule, is well tolerated and elicits robust responses comparable to PCV13 for shared serotypes while effectively broadening coverage to 15 serotypes when cross-protection against 6A is counted. For immunization programs weighing how to future-proof their pneumococcal strategies, this trial provides a substantial and encouraging body of evidence that broader serotype coverage need not come at the cost of safety or immunogenicity.

Subject of Research: Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine in Indian infants and toddlers

Article Title: Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial

Article References: Thuluva, S., Gunneri, S., Ningaiah, S., Yerroju, V., Mogulla, R. R., Dhar, C., Thammireddy, K., Desai, S., Paliwal, P., Loka, C., Esanakarra, R., Narayandas, S., Chakravarthy, B. S., Narayan, J. P., Mahantshetti, N. S., Narang, M., Karayar, R. A., Verma, S., Thakkar, P. A., & Prabhakar, J. P. (2026). Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14412-1

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14412-1

Keywords: pneumococcal conjugate vaccine, PNEUBEVAX 14, BE-PCV14, PCV13, infant immunization, serotype 22F, serotype 33F, invasive pneumococcal disease, India, phase IV trial, booster vaccination, Streptococcus pneumoniae

Tryptophan, known for its multifaceted biological roles, serves as a precursor for crucial molecules such as serotonin and melatonin, influencing neurological pathways and immune modulation. The notable depletion of tryptophan discovered in the breast milk of mothers living with HIV suggests a systemic alteration in amino acid metabolism triggered by chronic viral infection and immune activation. Given that approximately 1.3 million children worldwide are born annually to women living with HIV, the metabolic deficiency highlighted by this research may illuminate the underlying causes of increased morbidity and developmental impairments observed in these infants, despite effective prevention of vertical viral transmission.

Historically, children born to mothers with HIV but uninfected themselves have experienced elevated mortality rates and increased susceptibility to infections, growth failure, and cognitive delays, with mortality in low-resource settings reaching up to twice or thrice that of infants born to uninfected mothers prior to the advent of widespread antiretroviral therapy (ART). Intriguingly, even with the implementation of ART, these disparities persist, suggesting that viral suppression alone does not fully mitigate the metabolic disruptions or the inflammatory milieu affecting infant health. Until now, the biochemical and metabolic mechanisms contributing to these outcomes remained poorly understood, underscoring the significance of the present study’s metabolomic approach.

The UCLA team meticulously analyzed a vast repository of breast milk samples collected longitudinally from Zambian women enrolled in a clinical trial that spanned seven years, encompassing both HIV-positive and HIV-negative cohorts. Utilizing state-of-the-art metabolomic profiling techniques, over 800 distinct metabolites were quantified at multiple postpartum intervals, ranging from the neonatal stage through 18 months of lactation. To enhance the robustness of their conclusions, researchers conducted parallel validation in an independent cohort from Haiti, where all HIV-positive participants were undergoing antiretroviral treatment with improved immunologic profiles.

Findings revealed a consistent approximate 50% reduction in tryptophan concentrations in breast milk from HIV-positive mothers compared to controls across all time points. Moreover, an elevated kynurenine-to-tryptophan ratio was observed, a well-established biomarker indicative of heightened immune activation and indoleamine 2,3-dioxygenase (IDO) enzyme activity—a metabolic pathway often upregulated during chronic viral infections and systemic inflammation. These metabolic alterations in the milk were mirrored by decreased plasma tryptophan levels in the mothers, signifying that the depletion is not isolated to the mammary compartment but reflects a broader systemic deficiency possibly mediated by impaired intestinal absorption and sustained immune activation.

In addition to tryptophan metabolism perturbations, the research identified elevated levels of novel antiviral metabolites such as ddhC (3′-deoxy-3′,4′-didehydro-cytidine) alongside increased cytosine and dimethylarginine concentrations in the breast milk of women living with HIV. These molecules are biologically linked to chronic interferon signaling and innate immune responses, further corroborating the presence of persistent viral inflammation despite ART administration. Notably, these profound metabolic fingerprints persisted in the Haitian cohort, affirming their relevance and stability in the context of contemporary HIV therapy and enhanced immune status.

These insights into the altered amino acid metabolism and antiviral metabolite profiles raise compelling questions about the consequences for infant health and development. Tryptophan serves not only as a substrate for protein synthesis but also as a modulator of immune tolerance and neurodevelopmental processes. Deficiencies during critical windows of postnatal growth could underlie the increased incidence of infections, stunted growth, and neurocognitive impairments reported in HIV-exposed uninfected children. The kynurenine pathway metabolites, some of which exhibit neurotoxic properties, may further compound these risks, highlighting the delicate balance between immune activation and metabolic homeostasis in shaping infant outcomes.

Looking forward, the UCLA team stresses caution in translating these findings into clinical practice, emphasizing the complexities of tryptophan metabolism and its downstream pathways. Simple supplementation of tryptophan might inadvertently exacerbate neurotoxic metabolite accumulation if not coupled with interventions targeting the inflammatory cascade and enzymatic dysregulation. Ongoing and future studies will leverage animal models replicating chronic viral inflammation to investigate the safety and efficacy of potential nutritional interventions aimed at restoring metabolic equilibrium, enhancing immune resilience, and promoting optimal cognitive and physiological development in HIV-exposed infants.

Moreover, parallel research endeavors are planned to delineate whether infants born to mothers living with HIV experience systemic tryptophan depletion and altered metabolic processing—a critical extension that may uncover direct metabolic vulnerabilities in this population. Should nutritional or pharmacological strategies prove effective in these investigations, they could revolutionize neonatal care paradigms for the 1.3 million children exposed to HIV annually, reducing disproportionately high rates of morbidity and mortality in regions burdened by the HIV epidemic.

Reflecting on the broader implications, Dr. Grace Aldrovandi, corresponding author and professor at UCLA’s David Geffen School of Medicine, articulates that this study marks a seminal step in understanding the biological underpinnings that link maternal HIV infection to adverse infant health outcomes beyond viral transmission alone. Dr. Aldrovandi highlights that these metabolic insights open novel avenues for therapeutic innovation targeting not the virus per se, but the metabolic and immunologic sequelae that persist despite effective viral suppression. Complementing this perspective, Dr. Nicole Tobin, the study’s lead author, underscores the enduring nature of the metabolic signature, evident despite modern ART, and its explanatory power regarding the continuing disparities faced by these children. Together, these expert interpretations signal a paradigm shift in HIV maternal-child health research, emphasizing metabolic restoration as a frontier for improving long-term outcomes.

In conclusion, this landmark research elucidates a previously unappreciated dimension of HIV pathophysiology—chronic systemic and localized metabolic dysregulation manifesting in lactational biology—and its profound ramifications for infant health. By identifying tryptophan deficiency and heightened immune-metabolic activation in breast milk, the study provides a metabolic explanation for the lingering vulnerabilities of HIV-exposed but uninfected children. Continued interdisciplinary efforts integrating metabolomics, immunology, nutrition, and clinical medicine hold promise for developing targeted interventions that could transform the lives of millions of children born into the context of maternal HIV worldwide.

Subject of Research: People

Article Title: Altered milk tryptophan and tryptophan metabolites in women living with HIV

News Publication Date: 28-Oct-2025

Web References: https://doi.org/10.1038/s41467-025-64566-w

Keywords: Human immunodeficiency virus, Breast feeding